about
From bench to bedside: What do we know about hormone receptor-positive and human epidermal growth factor receptor 2-positive breast cancer?The PI3K/AKT/mTOR pathway in breast cancer: targets, trials and biomarkers.Deregulation of the EGFR/PI3K/PTEN/Akt/mTORC1 pathway in breast cancer: possibilities for therapeutic intervention.mTOR signaling for biological control and cancer.The PI3K/Akt/PTEN/mTOR pathway: a fruitful target for inducing cell death in rheumatoid arthritis?The combination of rapamycin and resveratrol blocks autophagy and induces apoptosis in breast cancer cells.P-mTOR Expression and Implication in Breast Carcinoma: A Systematic Review and Meta-AnalysisNew and emerging treatments for estrogen receptor-positive breast cancer: focus on everolimus.Effects of combining rapamycin and resveratrol on apoptosis and growth of TSC2-deficient xenograft tumors.ERRα Is a Marker of Tamoxifen Response and Survival in Triple-Negative Breast CancerTargeting Translation Control with p70 S6 Kinase 1 Inhibitors to Reverse Phenotypes in Fragile X Syndrome Mice.CDK4/6-inhibiting drug substitutes for p21 and p16 in senescence: duration of cell cycle arrest and MTOR activity determine geroconversion.Autophagy modulates cell migration and β1 integrin membrane recycling.Resveratrol prevents rapamycin-induced upregulation of autophagy and selectively induces apoptosis in TSC2-deficient cellsInhibition of GSK-3β activity can result in drug and hormonal resistance and alter sensitivity to targeted therapy in MCF-7 breast cancer cells.Aurora-A is a determinant of tamoxifen sensitivity through phosphorylation of ERα in breast cancer.Phosphorylated ribosomal S6 (p-rpS6) as a post-treatment indicator of HER2 signalling targeted drug resistance.The impact of PI3K inhibitors on breast cancer cell and its tumor microenvironment.LEM4 confers tamoxifen resistance to breast cancer cells by activating cyclin D-CDK4/6-Rb and ERα pathway
P2860
Q28084982-4668F3ED-B172-4309-82D0-6413421718C9Q33937368-324652D4-031C-4F27-AF12-0B3E9D4AAFF0Q34103963-FC83089A-D8D1-4138-B917-1CA5B6A920B6Q34330952-C440C9D6-09D0-406C-A7E2-2ADB3191CC66Q35680138-2A9FE427-FCFC-4EC2-B6B2-E12237225745Q35819635-9F0DA549-AAD2-41E1-9857-545EAF84BC5BQ36257635-B4710574-DF1C-404B-AA12-EC364D7C1DE6Q36547566-7C879A51-2097-4518-912A-625C9333F286Q36549186-A2E15DE3-3B3A-40E4-B4A2-88EFC4F37CF5Q36693175-4F8035CC-F885-4CB3-AD7A-7D42773CA1E9Q37006293-75383764-987E-42B9-8029-0F3A62704D15Q37420058-F174AC30-7C08-4EAD-8264-78F9E3550CC7Q37452981-B42F5B72-91BD-4CB0-A750-7B2A293AA98DQ37641525-5F252381-E3C6-4A57-A138-641B27780256Q37692593-1EDB1714-E401-4A2F-99F3-4DDD73BB2B5DQ37728635-77E54218-1DCC-479C-8A27-BE573F275211Q38838851-1A24160B-AD30-421A-9F12-173687FFBCB5Q55435506-D1CA62AF-28D0-4575-A3BC-3FF56ABCCB69Q57291547-B80898FD-C1E1-4E0C-8E75-5C7F76783C1A
P2860
description
2012 nî lūn-bûn
@nan
2012年の論文
@ja
2012年学术文章
@wuu
2012年学术文章
@zh-cn
2012年学术文章
@zh-hans
2012年学术文章
@zh-my
2012年学术文章
@zh-sg
2012年學術文章
@yue
2012年學術文章
@zh
2012年學術文章
@zh-hant
name
The role of S6K1 in ER-positive breast cancer.
@ast
The role of S6K1 in ER-positive breast cancer.
@en
type
label
The role of S6K1 in ER-positive breast cancer.
@ast
The role of S6K1 in ER-positive breast cancer.
@en
prefLabel
The role of S6K1 in ER-positive breast cancer.
@ast
The role of S6K1 in ER-positive breast cancer.
@en
P2860
P356
P1433
P1476
The role of S6K1 in ER-positive breast cancer.
@en
P2093
Marina K Holz
P2860
P304
P356
10.4161/CC.21194
P577
2012-08-16T00:00:00Z